ÌÇÐÄvlog

The Age-Related Eye Disease Study 2 (AREDS2) Research Group conducted a multicenter, double-masked clinical trial to determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery.

Suñer et al examined the benefit of ranibizumab (Lucentis) on measured reading speed, a direct performance assessment, through 6 months in eyes of patients with macular edema after retinal vein occlusion.

C. L. Shields and colleagues conducted a retrospective case series of 618 patients with conjunctival nevus, 32 of which had giant conjunctival nevus, to describe the clinical features and outcomes of giant (≥10 mm diameter) conjunctival nevus.

Sheyman et al report an outbreak of fungal endophthalmitis in a series of patients following intravitreal injection of combined bevacizumab and triamcinolone prepared by the same compounding pharmacy.

Baker et al estimate the incidence of central-involved macular edema 16 weeks following cataract surgery in eyes with diabetic retinopathy without definite central-involved diabetic macular edema preoperatively.

To investigate the clinical and retinal pathologic features of occult macular dystrophy, Ahn et al studied 46 eyes from 25 Korean patients using various imaging modalities. Quantitative and qualitative morphologic features were evaluated for their association with visual and electrophysiologic function.

Moore and Slabaugh evaluate the visual results and cost-effectiveness of surgical residents performing attending-supervised cataract surgery in a population of uninsured patients.

Mohney et al determined the incidence of optic nerve hypoplasia and the rate of associated endocrine, neurologic, and developmental abnormalities among a population-based cohort of pediatric patients.

Tse et al used comprehensive ocular and orbital histopathology to further document previously reported toxic effects observed with real-time ophthalmoscopy during superselective intraophthalmic artery chemotherapy in a nonhuman primate model.

Whitson and coauthors describe a low-vision rehabilitation program for patients with macular disease and cognitive deficits.